The presence of high numbers of circulating clonal plasma cells (cPCs) in patients with smoldering multiple myeloma (SMM), detected by a slide-based immunofluorescence assay, has been associated with a shorter time to progression (TTP) to MM. The significance of quantifying cPCs via multiparameter flow cytometry, a much more readily available diagnostic modality, in patients with SMM has not been evaluated. This study evaluated 100 patients with a known or new diagnosis of SMM who were seen at the Mayo Clinic, Rochester from January 2008 until December 2013. Patients with ⩾ 150 cPCs (N = 9) were considered to have high number of cPCs based on the 97% specificity and 78% PPV of progression to MM within 2 years of cPC assessment. The median TTP of patients with ⩾ 150 cPCs was 9 months compared with not reached for patients with o150 cPCs (P o0.001). Thus, quantification of cPCs via multiparametric flow cytometry identifies patients with SMM at very high risk of progression to MM within 2 years and warrants confirmation in larger studies. In the future, this may allow reclassification of such patients as having MM requiring therapy prior to them enduring end-organ damage.
INTRODUCTION
Multiple myeloma (MM) is preceded by an indolent phase such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM), depending on the extent of bone marrow involvement by the clonal PCs and monoclonal protein levels.
1,2 SMM is defined by the International Myeloma Working Group (IMWG) as the presence of a serum M-protein of ⩾ 3 g/dl and/or ⩾ 10% bone marrow plasma cells (BMPCs) with no evidence of end-organ damage such as hypercalcemia, renal insufficiency, anemia or lytic bone lesions. 2 Current practice guidelines for patients with SMM recommend monitoring with no active treatment. However, if patients with SMM who have a ⩾ 80% risk of progression to MM within 2 years could be identified, then early treatment of such patients may improve quality of life and overall survival rather than a strategy of observation until the development of end-organ damage. Recently, the IMWG recognized the presence of either free light chain (FLC) ratio ⩾ 100, 3, 4 BMPC ⩾ 60% 4, 5 or 41 focal lesion on skeletal MRI 6, 7 as myeloma-defining events (MDEs) in otherwise SMM patients due to their high risk of progression to symptomatic MM within 2 years. 8, 9 The presence of circulating clonal plasma cells (cPCs) is associated with a worse prognosis in patients with MM [10] [11] [12] and is also a risk factor for progression to MM in patients with MGUS and SMM. 13, 14 Specifically, our group has previously reported that high numbers of cPCs in patients with SMM predicted for early progression to MM within 2-3 years. 14 However, this study utilized a slide-based immunofluorescence assay to detect cPCs that has limited clinical availability due to its complexity. The adaptation of highly sensitive flow cytometry in clinical practice has improved the simplicity and sensitivity of detecting cPCs. Thus, we undertook this study of patients with SMM to examine the utility of detecting and quantifying cPCs via six-color multiparameter flow cytometry in predicting an imminent risk of progression to symptomatic MM within the following 2 years.
MATERIALS AND METHODS
We evaluated all patients with a known or new diagnosis of SMM who were seen at the Mayo Clinic, Rochester from January 2008 until December 2013 and who had their peripheral blood evaluated for cPCs by flow cytometry. Approval for this study was obtained from the Mayo Clinic IRB in accordance with the federal regulations and the principles of the Declaration of Helsinki. All patients gave written informed consent to have their medical records reviewed according to IRB and state of Minnesota requirements. The IMWG diagnostic criteria for SMM were utilized to confirm the eligibility of the patients included in this cohort, that is, the presence of a serum monoclonal Ig level ⩾ 3 g/dl, and/or bone marrow infiltration with monotypic PCs equal or exceeding 10%, in the absence of end-organ damage secondary to the plasma cell disorder. Patients with a diagnosis of MGUS or concurrent systemic AL-amyloidosis were excluded. Patients were excluded if they were treated with any form of chemotherapy within the previous 5 years or are being treated with ongoing or recent (o 5 years) high-dose corticosteroids (⩾15 mg prednisone daily or equivalent). The following laboratory data were abstracted from patients' electronic medical records for this analysis: hemoglobin, M-spike, total calcium, creatinine, β-2-microglobulin, serum FLC ratio, immunoglobulin (Ig) subtype quantification and immunofixation, 24 h urinary protein electrophoresis and immunofixation. The bone marrow biopsy and aspirates of the patients were evaluated for BMPC percentage, cytogenetics and fluorescent in situ hybridization results. Immunoparesis was identified as the reduction in the quantitative values of one or more Igs below the lower limit of normal of our laboratory's respective reference range.
Six-color multiparametric flow cytometry was performed on peripheral blood samples of the patients in this study. First, the mononuclear cells were isolated from each sample by Ficoll gradient. These mononuclear cells were then stained with antibodies to CD45, CD19, CD38, CD138 and cytoplasmic Kappa and Lambda Ig light chains. A Becton Dickinson FacsCanto II instrument (San Jose, CA, USA) was used to analyze 1 50 000 events using the BDFacs DIVA Software (San Jose, CA, USA). The plasma cells in the sample were identified by the strong expression of CD38, CD138, as well as the cytoplasmic Ig light chains. The cPCs were then differentiated from polyclonal or normal PCs by the presence of low CD19 and variable CD45 expression. The final number of cPCs detected was reported as the number of clonal events/1 50 000 collected total events. In those patient samples where o1 50 000 events were examined, the number of final clonal events was adjusted to 1 50 000 events. The lower limit of cPCs detection by this flow cytometry method is 20 cells/1 50 000 (0.013%). The Supplementary Figure 1 depicts an example of a flow cytometry pattern in a patient with SMM with kappa-restricted clonal cPCs.
Statistical analysis was performed using the SAS biostatistical software JMP 10.0.1 (SAS Institute, Cary, NC, USA). We identified a quantitative threshold for cPCs associated with the most optimal positive predictive value (PPV) of about 80% for progression of SMM to MM in the first 2 years after assessment of cPCs. The primary end point was time to progression (TTP) to MM. Two-sided Fisher's exact tests were used to test for differences between categorical variables. Two-sided Wilcoxon's rank-sum tests were used to compare continuous variables. TTP analysis was done using the Kaplan-Meier method. Differences between TTP curves were tested for statistical significance using the two-sided log-rank test unless otherwise specified.
RESULTS

Patient characteristics
There were 100 patients with a known diagnosis of SMM who had their peripheral blood evaluated by multiparametric flow cytometry for clonal cPCs within 6 months of their diagnosis and prior to disease progression. The median follow-up for this group was 37 months (95% confidence interval: 32-41). There were 31 (31%) patients who had progressed to MM requiring treatment at the time of last follow-up. There were 93 patients still alive at the time of study analysis. Those patients who had not progressed to MM had at least 24 months of follow-up from the time of their assessment for cPCs. At the time of cPC evaluation, there were 51 patients in this cohort who had Positron emission tomographycomputed tomography (PET/CT) evaluations and the remainder had whole-body skeletal bone radiographs to confirm the lack of lytic bone lesions associated with progression to MM. The median age of this cohort was 66 years (range: 34-85) and 51% were male. Of patients who progressed to MM, the distribution of symptoms at the time of progression is known for 30 patients and is illustrated in Figure 1 . Anemia (53%) was the most common symptomatic presentation associated with progression to MM warranting the initiation of systemic therapy. Only 13 (42%) of the 31 patients who progressed to MM had PET/CT evaluations at the time of progression. Only 56 patients had molecular cytogenetics results available for verification of which 6 had t(4;14) or deletion 17p abnormalities.
SMM patients with cPCs There were 24 patients (24%) who had detectable cPCs. The median number of cPCs was 78 per 1 50 000 events analyzed (range: 20-3124). The characteristics of patients with and without cPCs are listed in Table 1 . When compared with patients without Abbreviation: cPC, clonal plasma cell.
Circulating clonal plasma cells in smoldering multiple myeloma WI Gonsalves et al cPCs, patients with cPCs had a higher likelihood of having immunoparesis. We determined the various levels of cPCs and their sensitivity, specificity and PPV for disease progression within 2 years (Table 2 ). There was an increasing specificity and PPV for higher quantitative thresholds of cPCs. Patients with ⩾ 150 cPCs (N = 9) had a 97% specificity and 78% PPV of progression to MM within 2 years and hence the presence of ⩾ 150 cPCs was chosen as a cutoff to define high levels of cPCs (due to its nearly 80% PPV). We also tested if higher levels of cPCs improved the PPV of progression to MM within 2 years and found that patients with ⩾ 200 cPCs (N = 6) had a 100% specificity and 100% PPV of progression to MM within 2 years. The presence of ⩾ 150 cPCs is equivalent to 0.1% of the 1 50 000 mononuclear cells or events evaluated.
Factors predicting risk of progression The median TTP of patients with SMM to MM with cPCs (N = 24) was 10 months compared with not reached for patients without cPCs (N = 76) (P o 0.001) ( Figure 2 ). The progression to MM within 24 months was 58% for patients with cPCs compared with 9% for patients without cPCs (Po 0.001). When utilizing a cutoff of 150 cPCs, the median TTP of patients with ⩾ 150 cPCs (N = 6) was 9 months compared with not reached for patients with o 150 cPCs (N = 94) (Po 0.001) ( Figure 3 ). There were 78% of patients with ⩾ 150 or more cPCs who progressed to symptomatic myeloma within 24 months compared with 15% of patients with o150 cPCs (P o 0.001). The median TTP of patients with an involved/uninvolved (i/u) FLC ratio48 (N = 58) was 45 months compared with not reached for patients with an (i/u) FLC ratio ⩽ 8 (N = 42) (P = 0.035) (Figure 4 ). Progression to MM within 24 months was 24% for patients with an (i/u) FLC ratio48 compared with 17% for patients with an (i/u) FLC ratio ⩽ 8 (P = 0.459). The median TTP of patients with immunoparesis (N = 79) was 60 months compared with not reached for patients without immunoparesis (N = 13) (P = 0.027) ( Figure 5 ). Progression to MM within 24 months was 25% for patients with immunoparesis compared with 0% for patients without immunoparesis (P = 0.008). The probability of any of the aforementioned overlapping risk factors for early progression of SMM to MM such as presence of cPCs, immunoparesis and (i/u) FLC ratio48 is demonstrated in Figure 6 . In two separate multivariable models including both (i/u) FLC ratio48 and presence of immunoparesis with either (a) the presence of cPCs or (b) the presence of ⩾ 150 cPCs, only the presence of cPCs (P o 0.001) and the presence of ⩾ 150 cPCs (P = 0.008) were independent predictors of progression to MM within 2 years. When using the validated Mayo Clinic risk stratification model for SMM, 15 18 patients had ⩾ 10% BMPC in addition to serum M-spike Figure 2) . Of the 56 patients with molecular cytogenetic results available, the median TTP of patients with either t(4;14) or deletion 17p mutations (N = 6) was 11 months compared with 38 months for the remainder (P = 0.086). Of these six patients with either t(4;14) or deletion 17p mutations, five or 83% had progressed to MM at last follow-up and four did so within 24 months.
MDEs apart from CRAB features There were 20 patients who had FLC ratio ⩾ 100; of these only 7 had any cPCs and only 3 had ⩾ 150 cPCs. The median TTP was 40 months in these patients with FLC ratio ⩾ 100. There were only three patients who had BMPC ⩾ 60%, none of whom had any cPCs and their median TTP was 17 months. Overall 22 patients had either 1 of the newly defined MDE, and when they were excluded from the analysis it left only 78 patients. Of these patients, the median TTP to MM in patients with cPCs (N = 17) was still 9 months compared with not reached for patients without cPCs (N = 61) (P o0.001). The progression to MM within 24 months was 59% for patients with cPCs compared with 5% for patients without cPCs (P o 0.001). Similarly, the median TTP to MM in patients with ⩾ 150 cPCs (N = 6) was 8 months compared with not reached for patients with o 150 cPCs (N = 72) (P o 0.001). The progression to MM within 24 months was 83% for patients with ⩾ 150 cPCs compared with 11% for patients with o 150 cPCs (P o0.002).
Overall survival in SMM from the time of assessment for cPCs Given the short follow-up time, the median OS from the time of assessment for cPCs was not reached for this cohort of patients. However, the estimated 3-and 5-year OS was 81% and 70% for patients with cPCs and 97% and 95% for patients without cPCs (P = 0.075), respectively. The estimated 3-and 5-year OS was 79% and 67% for patients with ⩾ 150 cPCs and 97% and 95% for patients with o 150 cPCs (P = 0.043), respectively (Supplementary Figure 3) .
DISCUSSION
The risk of progression of SMM to MM is 10% per year in the first 5 years, but then decreases to 3% per year in the following 5 years, and 1% per year thereafter. 15 This observation can be explained if patients with SMM are comprised of two separate groups: (1) a high-risk group consisting of patients with SMM who have disease that has already transformed to active MM and (2) a standard-risk group consisting of patients with a more indolent form of disease, similar to MGUS. The ongoing standard of care is to observe patients with a SMM due to the knowledge that a proportion of these patients are in the standard-risk group and can remain progression free for many years while being spared the toxicities of therapy. However, it is not always possible to identify the progression to MM and initiate therapy prior to the emergence of serious end-organ damage. 16 Thus, there has been an ongoing effort to identify the high-risk group of SMM patients who will likely progress to MM within 2-3 years of diagnosis in an attempt to decrease their risk of experiencing irreversible end-organ damage. Furthermore, recent randomized trial data have suggested that early intervention with novel agents may improve outcomes for such patients with high-risk SMM making it all the more important to accurately identify such patients. 17 Thus, most recently, the IMWG guidelines have recognized the presence of FLC ratio ⩾ 100, 3, 4 BMPC ⩾ 60% 4,5 and the presence of a single lesion on the MRI 6 as new MDEs due to their high risk of progression (⩾80%) to symptomatic MM within 2 years. 8 The presence of cPCs in patients with SMM likely represents a marker of more aggressive disease, as now the clonal PCs are able to sustain themselves independent of the bone marrow microenvironment. 14 Bianchi et al. 14 demonstrated that the presence of high cPCs defined as absolute peripheral blood PCs45 × 10 6 /l and/or 45% PCs per 100 cytoplasmic Ig-positive peripheral blood mononuclear cells identified patients with SMM at high risk of progression to MM (that is, 71% and 86% progressing to MM within 2 years and 3 years, respectively). However, this study utilized a slide-based immunofluorescence assay to detect cPCs, which has low sensitivity and limited clinical availability. Current flow cytometry techniques are more sensitive and reproducible. In addition, it can rapidly detect and quantify cPCs making it more likely to be adopted universally in the future.
This study expectedly demonstrates that the presence of cPCs detected by flow cytometry in patients with SMM predicts for a shorter median TTP (10 months vs not reached) ( Figure 2 ) and higher 2-year probability of progression (58 vs 9%) to MM compared with those patients with SMM without detectable cPCs. Furthermore, increasing number of cPCs led to higher PPV and specificity of identifying patients with SMM progressing to MM within 2 years of their cPCs assessment by flow cytometry. Of the nine patients with ⩾ 150 cPCs, seven (78%) progressed to MM within 2 years leading to a PPV of 78% and specificity of 97%. The PPV and specificity offered by the cutoff of ⩾ 150 cPCs appears to be better than that provided by the current Mayo Clinic risk stratification system for SMM.
The presence of an abnormal serum (i/u) FLC ratio48 has been demonstrated to be a predictor of early progression to MM from SMM. 18 It has been hypothesized that clonal evolution of the premalignant PC to malignant PC leads to imbalances in the heavy and light chain production thus predicting for a shorter TTP in SMM. 18 Similarly, in this study serum (i/u) FLC ratio48 also predicted for shorter TTP in SMM patients, however, only 24% of patients progressed to MM within 24 months (Figure 4) . The presence of immunoparesis has also been shown to be a predictor of early progression to MM in both MGUS and SMM. 19 In this study, patients with no immunoparesis (~13%) had no progression in MM based on their short median follow-up time of 30 months. The role of immune system impairment in the risk of progression to MM has also been suggested by Paiva et al., 20 suggesting that high-risk SMM patients have an impaired immune system. Also, treatment with immunomodulators such as lenalidomide results in therapeutic immunomodulation associated with marked increases in functional T-lymphocytes and NK-cells to delay the progression to MM. 20 Nevertheless, only the presence of either any cPCs or just ⩾ 150 cPCs were independent predictors of progression of SMM to MM within 2 years of cPC assessment in multivariable models that included both (i/u) FLC ratio48 and the presence of immunoparesis.
The EuroFlow-International Myeloma Foundation (IMF) next generation flow (NGF-MM) minimal residual disease (MRD) panel has been in development by the EuroFlow Consortium and the IMF for ultrasensitive and standardized detection of MRD in MM. This NGF-MM approach analyzes between 2-15 million events per sample compared with 1 50 000 events per sample in this study and is likely to be the standardized approach for MRD detection for MM in the future. This approach has been recently adopted for the high-sensitive detection of cPCs and has detected them in virtually every SMM patient with a median absolute cPCs of 0.14 cPCs/μl (range: 0.022-14.58 cPCs/μl) and a median percentage of 0.0026% (range: 0.0002-0.23%). 21 The lower limit of detection of cPCs by the flow cytometry methodology used in this study is only 0.013%. Similar studies evaluating the utility of the new EuroFlow methodology in quantifying cPCs in SMM patients to identify a numeric cutoff predictive of early risk of progression should be done in the future if we are to adopt a universal standard.
There are several limitations to this study that need to be taken into account. First, the sample size is relatively small since this is a rare plasma cell disorder and the six-color multiparametric flow cytometer was utilized in clinical practice only over the last 8 years. Second, not all patients had their peripheral blood assessed for cPCs at the same time of their original bone marrow biopsy confirming the diagnosis of SMM. Thus, it is not possible to know whether at the time of assessment for cPCs whether the BMPC% could have already increased to ⩾ 60%, implying a high-risk status and currently defined as a MDE. 8 Similarly, none of the patients with SMM at this institution underwent whole-body skeletal MRI imaging to assess for focal myeloma lesions, which has also been included as an MDE. 8 We were unable to assess the utility of the Spanish model for risk stratification of SMM in our cohort of patients since we did not routinely utilize the same flow cytometry methodologies to determine the percentage of aberrant PCs in the BMPC compartment. 19 Hence, we were only able to assess the prognostic effect of the Mayo Clinic model. 15 Finally, majority of patients were not followed routinely with PET/CT scans, which has been recently found to be useful in detecting early-myelomarelated osteolytic bone lesions thus possibly underestimating the number of patients that progressed. 22, 23 Nevertheless, our study still demonstrates the utility of quantifying cPCs by multiparameter flow cytometry to identify patients with SMM at very high risk of progression to MM. Additional studies to further evaluate the cPCs using NGF-MM flow cytometry methodology should be pursued in ongoing, as well as future clinical trials for patients with SMM. This will allow us to consider the initiation of therapy in such high-risk SMM patients prior to them enduring end-organ damage.
